Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
Lori Jean Sokoll, Ph.D.
Professor of Pathology
Lori J. Sokoll, Ph.D., FACB is Professor of Pathology in the Johns Hopkins University School of Medicine and has secondary appointments in Oncology and Urology. She is Associate Director of the Clinical Chemistry Division and Director of the Special Chemistry Laboratory in the Johns Hopkins Hospital.
Dr. Sokoll has over twenty years of experience in laboratory testing for clinical and research purposes. As part of her clinical service in the Core Laboratories, she oversees immunoassay, endocrine, and tumor marker testing. Her research interests are focused on the measurement, evaluation, and clinical applications of cancer biomarkers, with a specific concentration on tumor markers for prostate cancer.
Dr. Sokoll received her A.B. degree from Cornell University, Master of Clinical Chemistry from Hahnemann University, and Ph.D. from Tufts University. She completed a two-year ComACC-accredited Postdoctoral Fellowship in Clinical Chemistry at the Johns Hopkins Medical Institutions.
- Professor of Pathology
- Professor of Oncology
- Professor of Urology
- B.A., Cornell University (New York) (1983)
- Ph.D., Tufts University (Massachusetts) (1995)
Research & Publications
My primary research interest is the investigation of serum tumor markers for the early detection, diagnosis, staging, and monitoring of cancer. Our focus is to develop new tumor markers and to develop new applications for existing markers in order to increase their clinical utility. We are primarily studying markers for prostate cancer and breast cancer. Other research interests include immunoassay automation and intraoperative hormone measurements.
Selected PublicationsView all on Pubmed
Sokoll, LJ, Rai AJ, Chan DW. Tumor Markers. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics, 5th ed. Philadelphia: W.B. Saunders Company, 2012:617-68.
Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliott D, Veltri R, Epstein JI, Partin AW, Carter HW, Trock B, Sokoll LJ. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 2012:188:1131-6.
Li QK, Nugent SL, Straseski J, Cooper D, Riedel S, Askin FB, Sokoll LJ. Thyroglobulin measurements in fine-needle aspiration cytology of lymph nodes for the detection of metastatic papillary thyroid cancer. Cancer Cytopath 2013;121:440-8.
Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, Lotan Y, Kibel AS, Busby JE, Bidair M, Lin DW, Taneja SS, Viterbo R, Joon AY, Dahlgren J, Kagan J, Srivastava S, Sanda MG. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol 2014;32:4066-72.
Amukele TK, Sokoll LJ, Pepper D, Howard DP, Street J. Can unmanned aerial systems (drones) be used for the routine transport of chemistry, hematology, and coagulation laboratory specimens? PLoS One 2015;10:e0134020.
Sokoll LJ, Zhang Z, Chan DW, Reese AC, Bivalacqua TJ, Partin AW, Walsh PC. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy? J Urol 2016;195:330-6.